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Abstract
Purpose: To perform film-based verification of 4D dose reconstruction to moving targets during
lung stereotactic body radiation therapy (SBRT).
Introduction: Current patient-specific quality assurance measures to test deliverability of plans
with dynamic intensity modulation involve delivering beams to static measurement device and
comparing the planned dose to measurement. However, motion-induced dose errors are not
detected with static measurement. Previous studies have investigated combining machine log data
with respiratory tracking to determine moving-target dose. By combining machine log data with
anatomic and density information at each breathing phase from 4D-CT, intrafraction anatomical
deformation due to respiration may be accounted for. However, to our knowledge, a film-based
verification of dose reconstruction using machine log data, intrafraction respiratory tracking, and
4D-CT has yet to be performed.
Methods: Lung SBRT plans were anonymized for 12 patients treated at our institution. Treatment
plans were copied onto known geometry (programmable respiratory phantom) and dose was
computed. Each SBRT plan was delivered to the phantom twice; first using 3 sec/breath (SPB),
again at 6 SPB. Respiratory traces were acquired during treatment. Logfiles were acquired after
treatment and partitioned according to breathing amplitude. Next, in-house code was used to
import logfile beams into the treatment planning system. Dose was computed on each 4D-CT
image using the imported beams and deformably accumulated. The accumulated, planned, and
measured doses for each plan and breathing rate were compared using gamma analysis.
Results: Gamma passing rates (GPR) (3%, 2mm, 10% threshold) of 4D dose reconstruction vs.
planned dose were >94% (mean 98.9% range 94.1%-100%) for all plans at each breathing rate.
No significant difference was found between the 3 and 6 SPB GPRs (p=0.310). Overall, the 4D
xii

dose reconstructions were found to better agree with film measurement, within the tumor motion
extent, than the treatment plan for both breathing rates (3 SPB: p=0.013, 6 SPB: p=0.017).
Conclusions: Log file-based dose reconstruction was verified using film measurement for 12 lung
SBRT plans delivered to a respiratory motion phantom. We showed that, given predictable
phantom motion, 4D dose reconstruction resulted in significantly higher GPR compared with film
than treatment plan to static geometry.

xiii

Chapter 1. Introduction
Background and Significance
Lung Cancer
Lung cancer comprises 1 out of 8 new cancer cases and has a 5-year survival rate of less
than 20%, making it the leading cause of cancer-related death in the United States. Approximately
6% of men and women will be diagnosed with lung cancer during their lifetimes (NCI 2019). The
majority (85%) of lung cancer cases are an aggressive form known as non-small cell lung cancer
(NSCLC), which is resistant to conventional radiation therapy techniques and chemotherapy.
Thus, the most effective treatment for early-stage NSCLC is surgical resection (NCI 2019).
However, many lung cancer patients are not surgical candidates, either from being medically
inoperable or refusing surgery. For patients with medically inoperable stage-I NSCLC, an
advanced radiotherapy technique known as stereotactic body radiation therapy (SBRT) has been
shown to have similar efficacy to surgery (Onishi, et al. 2011).
Stereotactic Body Radiation Therapy
Radiation therapy is the use of particulate or electromagnetic radiation to treat disease.
Radiation can have a therapeutic effect in several ways; the most notable is reproductive death of
cells via mitotic catastrophe in which a cell attempts to divide using damaged DNA. The most
probable mechanism of DNA damage varies among radiation type. For photons, most probable is
indirect action, in which radiation interactions result in formation of free radical oxygen molecules
capable of damaging DNA. However, if given enough time between radiation events, a cell may
be able to repair sublethal damage to its DNA. Normal tissues are better at repairing damaged
DNA than cancer. By fractionating a prescribed dose of radiation over many separate treatments
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(e.g., once per weekday for six weeks), rapidly dividing normal tissues can repair sublethal
radiation damage and acute detrimental health effects of radiation are reduced (Liu, et al. 2012).
Linear accelerators (linacs) are used to produce the x-rays used for radiation therapy. To
generate these x-rays, electrons are accelerated using microwave energy to MeV energies before
striking a tungsten target. The acceleration of the electrons by the electric field of the tungsten
nuclei results in the release of bremsstrahlung x-rays. This radiation is forward-directed
(Faddegon, et al. 1990), which compromises the flatness of the radiation field delivered to the
patient. To flatten the field, a flattening filter, thicker in the middle and decreasing thickness
radially, is placed in front of the x-ray beam. Since the beam is selectively attenuated in the middle,
flatness is improved at the patient (Vassiliev, et al. 2006). However, the flattening filter by
principle removes x-rays from the beam, which results in a decreased dose rate and increased
treatment duration.
Conventional radiation therapy involves between 10 and 30 fractions with 1.8-3 Gy
delivered per fraction. In contrast with conventional fractionation, a course of SBRT typically
consists of 1-5 fractions with 6-30 Gy delivered per fraction (Benedict, et al. 2010). Increasing
dose per fraction results in an increase of the radiation biological effect, which increases the
effectiveness of SBRT against NSCLC. To protect surrounding normal tissues, SBRT must be
delivered to the delineated target volume within millimeter margins (Shah, et al. 2013).
The linac may be operated in flattening-filter-free mode to increase the dose rate and
decrease treatment time. To further decrease treatment time, volumetric modulated arc therapy, or
VMAT, may be employed to deliver SBRT. VMAT is characterized by continuous delivery of
radiation dose during gantry rotation. Delivering radiation during gantry rotation reduces treatment
time, which increases patient comfort as well as daily patient throughput. VMAT seeks to optimize
2

dose delivery by utilizing complex beam apertures to modulate the fluence of a given field during
treatment while the gantry rotates around the patient. This fluence is modulated by binary multileaf collimators (MLCs), which are two banks of 0.5 cm-wide tungsten leaves that move
perpendicularly to the beam central axis to attenuate and conform the beam to a shape determined
by the computer optimization of dose objectives set during the planning process.
SBRT Treatment Planning and Motion Management
The first step in the radiation treatment planning process is to gather information for both
patient setup and dose calculation. This information is collected from a computed tomography
(CT) simulation, in which a scan of the patient is taken on a specialized CT scanner with a table
that simulates the treatment table. This specialized table allows the patient to be positioned and
immobilized just as they would be during treatment. These CT images are exported to the
dosimetrist, and the treatment is planned under the assumption that the CT image will represent
the patient throughout the course of treatment. CT image pixel intensity values are calibrated to
represent x-ray attenuation at their geometric location within the image. These intensity values are
converted to Hounsfield units (HU) during image processing, which are proportional to the linear
attenuation coefficient. The linear attenuation coefficient is a measure of the probability of energy
deposition at that location. Commercial treatment planning systems (TPSs), such as Pinnacle 3
(Philips Radiation Oncology Systems, Fitchburg, WI, USA), combine information on the energy
spectrum and fluence of the beam with the attenuation coefficients from the CT image set to
compute radiation dose (Papanikolaou and Stathakis 2009).
While the planning CT scan provides only a snapshot of tumor location during the scan,
respiratory correlated CT, or 4D-CT, is used to account for tumor motion during the planning stage
for lung SBRT. This imaging technique allows the physicist to determine the extent of tumor
3

motion that occurred during the scan. 4D-CT is standard-of-care for patients in the simulation
phase of lung SBRT treatment (Brandner, et al. 2017). To incorporate the motion of the tumor in
the planning phase, an internal target volume (ITV) containing the range of tumor motion during
the 4D-CT scan is contoured onto the maximum intensity projection (MIP) of the 4D-CT image
set as shown in Figure 1.1.

.
Figure 1.1. Delineation of tumor motion extent using maximum intensity projection. Left: 4DCT image of phantom at amplitude position 0.0. Center: Maximum intensity projection (MIP)
over all 4D-CT images. Right: MIP contours; internal target volume containing motion (ITV,
cyan) and planning target volume including setup margin (PTV, red = ITV + 0.5 cm).
The MIP gives the planner a visualization of the full range of motion of the tumor. The
planning target volume (PTV) is created for lung SBRT by expanding the internal target volume
by a setup margin, 5 mm according to the Radiation Therapy Oncology Group (RTOG) 0813
protocol. The setup margin accounts for variance in day-to-day patient alignment. The prescription
dose is planned to be conformally delivered to the PTV. Using computer optimization in the
planning system, VMAT SBRT beams are planned to meet treatment goals, such as target dose
heterogeneity, PTV dose coverage, and normal tissue dose allowance.
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Effects of Tumor Motion on Delivered Dose
Respiratory motion can affect the location of abdominal and thoracic tumors during planning
as well as treatment. The delivered dose to the moving target may deviate from the statically
planned dose via two effects: (1) gradient effect and (2) interplay effect (Jiang, et al. 2003).The
gradient effect may be thought of as the ‘smearing’ of the dose distribution along the principle axis
of tumor motion. This smearing occurs when the moving target passes through heterogeneities in
the static dose distribution and is present in any radiation treatment modality. Interplay effect, in
contrast, is only present in treatments with dynamic intensity modulation. Interplay effect can be
described as the destructive or constructive interference between the tumor motion and moving
MLC aperture (Stambaugh, et al. 2013). Computer optimization in VMAT or intensity-modulated
radiation therapy (IMRT) planning involves a numerical optimization of plan objectives which
may result in beam shapes that do not always contain the full target volume (Bortfeld, et al. 2002).
Hence, part or all of the tumor may be outside of the radiation field at given times during treatment,
reducing tumor dose and increasing dose to normal tissue.
Bortfeld, et al. found, using the Central Limit Theorem, that the probability density function
of the dose to a given point becomes near-Gaussian after about 5 fractions (Bortfeld, et al. 2002).
The low number (5 or fewer) of fractions in an SBRT treatment regimen may inhibit these errors
from being ‘averaged out’. The interplay effect can result in significant dose deviations. Jiang, et
al showed inter-fraction dose delivery variation of up to 30% for single-field IMRT, and up to
18% for 5-field IMRT (Jiang, et al. 2003). Court, et al. showed that for 2-arc VMAT, interplay
effect becomes more significant as breathing rate decreases and amplitude of motion increases
(differences as great as 5% for 2cm motion at 5 SPB) (Court, et al. 2010). Kubo, et al. showed
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dose differences of up to 10% between successive film measurements in a programmable
respiratory phantom (Kubo, et al. 2018).
Motivation for Research
Patient-specific quality assurance (QA) measures use a static 2D diode array for verification
measurement, which does not account for the effect of motion on the absorbed dose to the target
region. The delivery log file written by the linac during each treatment has been previously studied
as a way to provide a way to compute the delivered dose to a moving target, if combined with
intrafraction respiratory data. Poulsen et al. proposed an efficient log file binning methodology,
through which they reconstructed delivered dose to moving targets by reformatting the log file into
a motion-mimicking treatment plan using isocenter shifts (Poulsen, et al. 2012). Zou, et al.
proposed a log file 4D-binning methodology, using deformable image registration to map doses
from each 4D-CT phase image to a reference phase, and simulated motion effects during VMAT
lung SBRT (Zou, et al. 2014). Chung, et al. applied the isocenter shift method of Poulsen et al.
and correlated the tracked respiratory signal with measured tumor displacement from the 4D-CT
dataset (Chung, et al. 2018). Meijers, et al. applied log file-based 4D dose accumulation to evaluate
moving target dose in pencil beam proton therapy (Meijers, et al. 2019).
Log file-based dose reconstruction for moving targets, utilizing the patient 4D-CT dataset, is
less well-established than the method of isocenter shifts. To our knowledge, an end-to-end
verification of the 4D-CT-based procedure for retrospective QA has yet to be performed. 4D-CT
may provide advantages to log file dose reconstruction over to the isocenter shift method, such as
information on the patient anatomical deformation due to respiration at each breathing phase, as
well as deformation of the tumor. In addition, we find no publications utilizing Elekta delivery log
files for reconstructing dose to a moving target. This study seeks to perform an end-to-end
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verification of log file-based dose reconstruction using 4D-CT and utilizing Elekta log files. In
addition, we seek to study the effect of breathing rate on the resultant dose accumulations.
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Chapter 2. Methods and Materials
Patient Selection, Phantom Imaging, and Treatment Planning
Retrospective Patient Selection and Anonymization
The patients for the anonymized cohort were selected using the criteria presented in Table
2.1. The most restrictive criterion was the respiratory motion management strategy, as many lung
SBRT patients in our clinic are treated employing breath-hold techniques. The final sample size
meeting our criteria was 12 patients.
Table 2.1 Patient selection criteria.
Criterion

Requirement

Lung Left or Right

Either

Intra-lung tumor location

Any

Dose per Fraction

 10 Gy

Number of fractions

 5 fractions

Superior-inferior motion

 5 mm

Motion Management Strategy

Free-breathe

Beam Energy

6 MV flattening-filter-free

Patients in the cohort were anonymized using Mobius3D software (Varian Medical
Systems, Palo Alto, CA). Anonymized RT Plan files were downloaded from Mobius3D and
imported into the MOSAIQ Radiation Oncology (Elekta AB, Stockholm, Sweden) record and
verify system via the RTP Import function to retrieve the SBRT plans to be delivered. Each patient
was simulated using the Quasar Respiratory Motion Phantom.
Quasar Respiratory Motion Phantom
The Quasar respiratory motion phantom (Modus Medical Systems, London, ON, Canada)
features a body oval, cedar ‘lung’ cylindrical insert with acyclic tumor, and a drive motor which
moves the lung insert and stage. Figure 2.1 presents an annotated image of the Quasar phantom,
and Figure 2.2 shows an axial CT image of the Quasar phantom.
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Figure 2.1. Image of Quasar Respiratory Motion Phantom.
The amplitude of motion of the lung insert in the superior-inferior direction can be set
manually or controlled via software. Software control can be performed using an external
computer connected to the phantom via a local network connection and using the accompanying
software package . Fiducial markers on the sides (pictured in CT image) and top of the phantom
allow alignment of the phantom with room lasers for imaging or beam delivery.

Figure 2.2. Axial computed tomography image of Quasar Respiratory Motion Phantom.
Several cylindrical insert types are available for the phantom, including an ion chamber
insert, halved tumor insert, and film cassette.
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4D-CT Acquisition
Respiratory-correlated CT, or 4D-CT, is an imaging technique in which a series of CT
images taken during respiration are sorted according to the respiratory cycle. The respiratory cycle
is tracked during the scan using an external fiducial marker. The position of this marker’s motion
over time results in a respiratory trace. To acquire a respiratory trace for image binning, breathing
motion is tracked during the scan using an external surrogate signal; e.g., an IR reflector box set
on the patient’s abdomen. The external surrogate signal is used to bin images to the section of the
patient breathing cycle in which they were acquired. These sections are known as breathing phases.
4D-CT scans were acquired of the moving Quasar respiratory phantom simulating a sin6
breathing pattern for each amplitude in the patient cohort. The sin6 wave was defined as
sin6(𝑡) = 𝐴 sin6 (

𝜋𝑡
)
𝑇𝐵

(2.1)

where 𝐴 is the peak-to-peak amplitude of motion in the superior-inferior direction and 𝑇𝐵 is the
breathing period, usually presented in seconds-per-breath (SPB). Figure 2.3 presents a plot of a
sine6 wave.

Full-inhale

Full-exhale

Figure 2.3. Sin6 wave used to represent human breathing cycle.
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The sin6 function was used because it is characterized by long full-exhale position and
short full-inhale position, which better represents a human breathing cycle than a sine wave. This
respiratory-mimicking waveform was imported as a text file into the Quasar Programmable
Respiratory Phantom software (Modus Medical Systems, London, ON, Canada), in which the
waveform could be scaled to match a given amplitude and frequency. For our 4D-CT acquisition,
we used a breathing period of 6 SPB.
This amplitude was set to be the peak-to-peak distance of the sin6 wave. To simulate right
and left lungs, the phantom was rotated on the table so that the cedar ‘lung’ insert matched patientleft or patient-right. An IR reflector box was positioned on top of the phantom stage, and motion
tracking was performed using the Varian Real-time Position Monitoring (RPM) system. The
Varian RPM system is a clinical external surrogate marker tracking system which utilizes an IR
camera. Images were acquired using a GE LightSpeed 16RT CT scanner (GE Healthcare, Chicago,
IL) and clinical 4D gating protocol.
The clinical 4D gating protocol begins with a scout CT scan, which is a static X-ray scan
taken to localize the target and select the imaging volume for the following scans. Next is a 3D
helical CT scan, which was skipped for our procedure as it was not used for our treatment planning.
Finally, the last scan in the protocol is a cine scan. During the cine scan, the CT table remains fixed
while the x-ray tube rotates around the patient for a duration of time within which a full breathing
cycle takes place. After this duration of time has ended, the x-ray tube turns off and the table
indexes in the cephalocaudal direction by the axial slice thickness, nominally 2.5 mm, to the next
position. Then, the x-ray tube turns back on and another full breathing cycle is captured. Finally,
this process is repeated until the scan length indicated by the scout CT localization has been filled.
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The cine image acquisition process results in CT data acquisition at each successive table
position from which CT images are reconstructed. To reconstruct cine images, these CT data are
sorted into bins corresponding to divisions of the respiratory cycle, called phases. We used a
clinically ‘long’ breathing rate of 6 SPB used during the CT scan, to reduce the tumor speed and
thus reduce motion artefacts. To ensure enough time for both a full breathing cycle image capture
with time for reconstruction, the cine time, or the duration at which the table is at each index and
the x-ray tube is on, is set to the duration of the breathing cycle plus a nominal tube ramp-up time
of two full CT rotations. For our 6 SPB breathing period, this value was 7.7 seconds. Scan
parameters are provided in Table 2.2.
Table 2.2. Cine scan parameters for 4D-CT acquisition.
Cine Scan Parameter

Value

X-Ray Tube Voltage

120 kV

X-Ray Tube Current

400 mA

Slice Thickness

2.5 mm

Cine Time Between Images

0.15 s

Cine Time

7.7 s

Cine image sets are much larger in file size than conventional CT images, and the limiting
factor in our sampling was the number of images allowed for a single scan, which is limited to
under 3,000. Using the parameters in Table 2.2., for a full scan length including the full body of
the phantom, the resulting image set contained 2,632 images and any further changes resulted in
an image set that was greater than the limit.
After the images were acquired, the motion amplitude data with timestamps were exported
from the RPM system and the cine images were transferred to MIM software (MIM Software Inc.,
Cleveland, OH). Using MIM, the cine images were binned according to the motion data, which
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resulted in a 4D image set, and the cine file was removed from the MIM server and stored
externally. Amplitude-based binning was employed to bin the 4D images.
Treatment Planning
The time-weighted average intensity projection (AIP) image was exported from MIM to the
Pinnacle3 treatment planning system. The average intensity projection image has been shown be
less prone to image artefacts than free-breathe CT, while being nearly equivalent dosimetrically to
the free-breathe CT (Tian, et al. 2012). For this reason, we used the AIP image of the phantom for
computing our static treatment plans. Each patient’s clinical lung SBRT VMAT beams were
retrieved from the MOSAIQ record and verify system (Elekta AB, Stockholm, Sweden) as a text
file containing each beam’s control points. A VMAT beam consists of many control points (usually
50+) along the arc traced by the gantry rotation; at each of these points the beam shape, machine
output, gantry orientation, etc., are specified. Control points were manually imported using the
scripting interface within the Pinnacle3 treatment planning system.
Using the known geometry of the Quasar phantom, in which the center of the tumor is 80
mm lateral to the center of the phantom, the isocenter was manually and consistently set. The
treatment isocenter was consistently placed at 0 mm in the superior-inferior direction, and 80 mm
laterally. For left-lung beams, +80 mm was used; for right-lung beams, -80 mm. The couch was
removed from the dose computation. Finally, the dose grid was specified with resolution 2mm x
2mm x 2mm. For consistency between plans, a script was used to set the isocenter, remove the
couch, and define the dose grid. Dose was computed using the Pinnacle 3 Adaptive Convolve
algorithm.
Due to geometrical differences between the real patients and the phantom, the computed
dose distributions within the phantom did not exactly match the planned dose distributions within
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the real patients. Specifically, the dose distributions within the target volume (PTV) may contain
hot and cold spots and the dose falloff regions may be present within the PTV, due to the phantom
geometry. Thus, the plans may be systematically less representative of the moving target dose
because motion effects may be exaggerated due to the spherical tumor moving through the dose
heterogeneities. However, this is advantageous in assessing the accuracy of the 4D dose
reconstruction, as the likelihood of motion-related dose variance is increased while the mechanical
delivery conditions of clinical SBRT are preserved.
Treatment Delivery and Reconstruction of Moving Target Dose
Treatment Delivery Experimental Setup
Figure 2.4 presents the experimental setup for treatment delivery to the phantom.

Elekta Agility
Treatment Head

Motion
Tracking
Camera

Quasar
Respiratory
Phantom
t
Figure 2.4. Experimental setup for beam delivery to phantom.
For each trial in the study, radiochromic film was cut so that it fit within the cylindrical
Quasar phantom lung insert. The radiochromic film was used to measure dose to the moving target.
CT-visible markers were placed on the film for registration with the CT coordinate system. Next,
the cylinder was placed back inside the acrylic body of the phantom and the stage was set to its
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home position. The phantom was controlled using the Quasar Respiratory Motion Software, which
was set to produce the desired respiratory amplitude for each patient. Motion was tracked using
the in-house external surrogate tracking camera system. Beams were delivered using an Elekta
Versa HD linear accelerator with Agility treatment head (80 MLCs per bank) (Elekta AB,
Stockholm, Sweden). After the beams were delivered, a CT scan of the phantom was taken to get
the CT coordinates upon which to register the film.
Treatment Delivery Log File
During treatment, a delivery log file is written in real time at a sampling rate of 4 Hz. This
file contains beam information as a function of time, such as monitor units, gantry angle, and MLC
positions. Following each treatment delivery, log files were retrieved from Mobius Log software
(Elekta AB, Stockholm, Sweden) which returns the log files from the linac control system via a
local network connection. While the timestamps recorded in the logfile are relative to the starting
time, the header information of the log file contains the datetime string of the first timestamp, and
thus the true time of each row of logfile data could be determined. The synchronization of the log
file timestamp with the respiratory trace was verified.
In-House External Surrogate Tracking System for Treatment Vault
The platform of the Quasar phantom moves up and down (anterior-posterior direction) with
the forward and backward (superior-inferior) motion of the cylindrical lung insert. This motion is
1:1; that is, 1 cm of movement of the cylindrical lung insert translates to 1 cm of platform
movement. Thus, for our trials with only 5 mm of total motion, the platform and therefore our
surrogate marker only moves 5 mm. This necessitated a camera system which was reliable yet
inexpensive, since the camera would need to be placed very close to the radiation field to capture
a usable signal. We used a Logitech C270 webcam, which outputs 720p video at a framerate of 30
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Hz, for our tracking purposes. Each frame of the live video feed was used to track the center of a
circle using in-house Python code. To initiate tracking, the user was able to click within the circle.
This click location was used as a guess to compute the center of the circle. The computed (x, y)
center was used as the guess for the next frame. This method was found to be stable for the external
marker motion speeds studied in this project.
Verification of Log File Synchronization with Camera
To partition log file data using motion data from our in-house system, it was necessary to
verify that the timestamps recorded in the log file were synchronized with the timestamps returned
by our motion tracking code. This was accomplished by tracking the gantry angle with our motion
tracking system during treatment delivery and comparing the tracked gantry angle to the recorded
gantry angle in the log file at each timestamp. A white circle with black background was taped to
the false wall which rotates with the linac. The camera system was initialized to track the circle on
the wall as the gantry rotated during beam delivery. Using the x, y coordinates of the trace of the
gantry, the gantry angle was computed. Cross-correlation was used to determine whether any time
shift existed between the computed and tracked gantry angles.
Log File Partitioning
Log files from the linear accelerator were overlaid with respiratory tracking data taken from
the in-house webcam system. First, due to the limited resolution of the camera, a sin6 wave was
fit to the data using the peaks of the respiratory signal, which were found to be the most reliable
feature. The fit wave was normalized to the range [0, 1]. Next, the amplitude targets were copied
from the MIM 4D-CT binning settings. The amplitude targets used in this study were 0.0, 0.2, 0.4,
0.6, 0.8, 1.0, where 0.0 represents the lowest point of the wave and 1.0 represents the wave’s
highest point. Amplitude targets are shown in Figure 2.5.
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Figure 2.5. Amplitude binning targets for log file partitioning.
Next, the time at which each amplitude cutoff occurred was determined using linear
interpolation. After bin cutoff times were computed, log files were partitioned using the cutoff
times as dividing points. Each log file partition (log file data falling between sequential cutoff
times) was written to a temporary text file with the filename indicating the amplitude bin and
partition number within that bin. Since the sampling rates of the amplitude data and log file data
were asynchronous, linear interpolation was used to find the log file data values at the cutoff times.
These interpolated values were included in the partitions. In-house Python code was used to
convert the log file partitions into static beams within the Pinnacle3 treatment planning system
using the Pinnacle3 scripting interface.
For a log file partition containing 𝑁 rows (with a maximum of 2 interpolated rows of data
and minimum of 𝑁 − 2 rows of non-interpolated data from the log file), the number of static beams
written for that log file partition was 𝑁 − 1. More specifically, each static beam written to the
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import script was a composite of the 𝑖th- and 𝑖th + 1 row of the log file partition, 𝑃𝑖 and 𝑃𝑖+1;
scripted static beam parameters 𝑇𝑖 , such as gantry angle, collimator angle, etc., with the exception
of the beam output (MU), for the 𝑖th static beam were assigned by taking the average:
𝑇𝑖 =

𝑃𝑖 + 𝑃𝑖+1
2

(2.2)

Each amplitude bin was assigned a specified number of monitor units, 𝑀𝑈bin which was
computed using
𝑀 𝑁−1

𝑀𝑈bin = ∑ ∑(𝑀𝑈𝑖+1,𝑗 − 𝑀𝑈𝑖,𝑗 )

(2.3)

𝑗=1 𝑖=1

where 𝑖, 𝑗 represent the indices of the row (of 𝑁 rows) inside the partition, and partition (of 𝑀
partitions) inside the amplitude bin, respectively. The weight 𝑤𝑖,𝑗 of each scripted beam was taken
to be the monitor units (MU) delivered from the 𝑖th to the 𝑖th + 1 row of the partition, divided by
the total MU for that amplitude bin,
𝑤𝑖,𝑗 =

𝑀𝑈𝑖+1,𝑗 − 𝑀𝑈𝑖,𝑗
𝑀𝑈bin

(2.4)

Importantly, the sum of all weights for a given amplitude bin is unity,
𝑀 𝑁−1

∑ ∑ 𝑤𝑖,𝑗 = 1
𝑗=1 𝑖=1

A visualization of the log file partitioning process is presented in Figure 2.6.
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(2.5)

Figure 2.6. Log file partitioning visualization. The blue vertical shaded region indicates the log
file partition 𝑃 within the 0.6 amplitude bin, with the red horizontal shaded region indicating the
amplitude position target (in this case, 0.6) and the cutoff values of the bin (0.5, 0.7). Filled
circles correspond to log file data points, while the unfilled circles correspond to linearly
interpolated points. 𝑆𝑡𝑎𝑡𝑖𝑐1 and 𝑆𝑡𝑎𝑡𝑖𝑐2 correspond to the two static beams which are elements
of 𝑃. Symbols 𝜃 and 𝑥 correspond to the gantry angle and example MLC position, respectively.
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Deformable Dose Accumulation
Image registration, the process of mapping corresponding points between images, has
become ubiquitous in radiation therapy. There are two main types of image registration algorithms;
(1) rigid and (2) deformable image registration (DIR). Rigid registrations can be defined by a linear
transformation (e.g., rotation, translation) from a source image to a target image, in which there is
no deformation of the underlying image grid. An example application of rigid registration is daily
patient alignment using the on-board cone-beam CT prior to radiation treatment delivery. The
patient is scanned using the on-board imager, and the resultant images are aligned with the patient’s
planning CT scan to compute necessary table shifts and ensure consistent patient alignment from
one treatment fraction to the next. An example application of DIR, especially relevant to this work,
is the deformable registration from 4D-CT phase images to a reference phase. During breathing
motion, the patient remains stationary but the internal anatomy changes by stretching and
contracting. DIR allows a vector map to be drawn from corresponding points in one phase image
(the source) to another phase image (the target). The source image (i.e., where the vector field
mapping voxels from one image to another starts) is referred to in this work as the ‘secondary
image’. The target image (i.e., where the vectors point) is referred to as the ‘primary image’.
A review of DIR algorithms for dose accumulation has been published by Chetty and RosuBubulac (Chetty and Rosu-Bubulac 2019). In their review, the two major types of deformable
registration algorithms are described, which are spline-based and free form algorithms. Splinebased algorithms use features of the image to define control points and use spline functions to map
correspondences between those points. Free form algorithms, in contrast, allow the vectors for
each secondary image voxel to map freely to any voxel in the primary image. MIM v.9.6. provides
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a proprietary free-form DIR algorithm which attempts to find the most physically realistic mapping
for each voxel (Calusi, et al. 2019). The MIM DIR algorithm was used in this study.
Deformable dose accumulation is an application of DIR where dose values from the dose
grid of the secondary image follow the vector map to the corresponding grid points on the primary
image. We applied deformable dose accumulation in MIM software to map computed doses from
each amplitude position bin image to our reference position image. The reference position image
was defined to be at the time-weighted average position of the phantom lung insert during
treatment. Figure 2.7 presents the workflow used to deform log file partition doses onto the
reference image geometry.
Average Position Image

4D-CT Image (Position 1)

Compute Vector Field

Deformed Dose 1 to Avg Pos

Compute Dose to Pos. 1
Log File Bin (Position 1)
Average Position Image

Compute Vector Field
4D-CT Image (Position 2)
Log File Bin (Position 2)

Deformed Dose 2 to Avg Pos

Compute Dose to Pos. 2

4D Reconstructed Dose

Figure 2.7. Flowchart of deformable dose accumulation. For simplicity, only two positions are
shown; however, in practice we accumulated dose over all 6 position bins. Red dashed box
indicates dose accumulation on the time-weighted average position geometry.
Validation of Deformable Dose Accumulation
The combination of 4D-CT images of the Quasar phantom with the binned log file data
allowed us to reconstruct the beam apertures occurring at each tumor position. Thus, 4D dose
accumulation allows the computation of the delivered dose to the moving tumor which takes into
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account the interplay effect. To test our deformable dose accumulation method, we created an
IMRT Step-N-Shoot treatment plan which forced interplay effect to occur, delivered this plan to
the Quasar phantom, measured the dose delivered to the moving target, and compared our
measured moving-target dose with the 4D log file-based deformable dose accumulation. The
IMRT Step-N-Shoot plan forced interplay using an aperture, approximately the size of the tumor,
which moved aperiodically along the tumor’s principle axis of motion. Since the sine6 wave is
periodic, the aperiodic nature of the aperture position over time guaranteed that interplay (i.e.,
destructive interference) between the two motion patterns would occur.
Radiochromic Film Dosimetry
Radiochromic Film Calibration
Radiochromic film is a passive, integrating dosimeter with high spatial resolution that is
nearly tissue equivalent. It is widely used over radiographic film due to its self-processing and
insensitivity to ambient light (Devic, et al. 2016). Gafchromic EBT3 radiochromic film (Ashland,
Wilmington, DE) was used (Lot #: 05161905) for our film measurements. A cross-sectional
diagram of Gafchromic EBT3 film is presented in Figure 2.8.

Figure 2.8. Cross-section of Gafchromic EBT3 film (Ashland 2020).
Radiochromic film changes color when radiation dose is absorbed in it due to polymer
reactions caused by the radiation interacting within the film’s active layer. The color pixel values
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of scanned radiochromic film images are calibrated with absorbed dose so that radiochromic film
may be used for relative dosimetry. The dose response range of radiochromic film is up to 4000
cGy (Casanova Borca, et al. 2013). Our calibration included 14 points, which ranged from 0 cGy
to 3000 cGy. The calibration doses used were 0, 125, 250, 375, 500, 625, 750, 875, 1000, 1250,
1500, 2000, 2250, and 2500 cGy.
For each calibration point, a small (minimum 3 cm x 3 cm) rectangular section of film was
cut placed at reference depth under reference conditions. For our clinic, reference depth was 10
cm, and reference conditions included 10 cm backscatter, a 10cm x 10cm field size at isocenter,
and 90 cm source-to-surface distance (SSD). Each calibration film was placed at the center of the
square field. Solid water phantoms were used to create these reference conditions. Given these
reference conditions, the equation (Gibbons, et al. 2014) relating dose 𝐷 to machine output
(monitor units, MU), for the central axis reduces to
𝑀𝑈 =

𝐷
𝐷0̇

(2.6)

where 𝐷0̇ = 0.8 cGy / MU for 6 MV photons at our institution. This equation was used to convert
our known calibration doses into the MU setting in the linac control system for each calibration
film.
Calibration films were scanned >24h after exposure using an Epson Expression 10000XL
document scanner, following the recommendations of AAPM TG 55 (Niroomand-Rad, et al.
1998). Care was taken to ensure consistent orientation of the film, which was essential to mitigate
the effect of light polarization on the computed optical density (Perez Azorin, et al. 2016). Prior to
scanning film, a minimum of 10 warmup scans were run to ensure that the scanner operating
temperature was level. Table 2.3 presents the scanner settings used for our film digitization.
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Table 2.3. Film digitization parameters (Epson Scan Software).
Parameter

Setting

Mode

Professional

Resolution

150 dpi

Image Type

48-bit color

Document Type

Film

Save Format

TIFF

Film images were saved in tagged-image file format (TIFF). Next, the mean pixel values
for the red, green, and blue channels were found for each of the calibration films using a
rectangular selection window. These pixel values 𝑃𝑉 were converted into optical density 𝑂𝐷 using
the formula
𝑂𝐷 = − log10 (

𝑃𝑉
)
216 − 1

(2.7)

where 216- 1 represents the maximum pixel value for each color channel given the 48-bit color
setting (16 bits per color channel). A rational fit function was used to calibrate absorbed dose to
optical density as recommended by the manufacturer,
𝑂𝐷(𝑥) = −log10 (𝐴 +

𝐵
)
(𝑥 + 𝐶)

(2.8)

where 𝑥 is the absorbed dose, and 𝐴, 𝐵, and 𝐶 are the fit coefficients. The red, green, and
blue color channels of the film image were calibrated independently. A piecewise fit function was
utilized to accommodate the large dose range following a previously published methodology
(Morrison, et al. 2014). To implement this piecewise function, the OD for each fit curve (Red,
Green, and Blue) corresponding to the median dose over the whole range was determined and set
to be the cutoff point for its respective color channel. To ensure a smooth function at the cutoff
point, fit curves included the calibration doses immediately surrounding the cutoff point. Figure
2.9 presents the film densitometric curve used for calibration.
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Figure 2.9. Gafchromic EBT3 film densitometric calibration curve.
Radiochromic Film Image Processing
Radiochromic film does not have an inherent coordinate system that can be directly linked
to any CT image. Therefore, it was essential to register the film to a reference DICOM coordinate
system. To register the film, we used a point-based registration method. Consider two points (A,
B) on the film and corresponding CT coordinates (𝐴𝐶𝑇 , 𝐵𝐶𝑇 ). First, the pixel coordinates of points
A and B were determined on each film image. Next, each film image was rotated so that the line
passing through (A, B) was parallel to the line passing through (𝐴𝐶𝑇 , 𝐵𝐶𝑇 ). Finally, the film
coordinates were scaled and translated to match those of the CT to complete the rigid registration.
After the linear transformation for the registration was solved, each film image was denoised using
a median filter (5 px window), and then downsampled using a bilinear interpolation to a 1 mm x 1
mm grid.
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Data Analysis
Gamma Analysis
Gamma analysis provides a comparison between two dose distributions that takes into
account both dosimetric and geometric information to determine agreement (Low, et al. 1998).
Gamma analysis is performed by computing gamma indices at each point in a dose distribution.
The gamma value was defined by Low et al. as:

𝛤 (𝑟𝑚 , 𝑟𝑐 ) = √

𝑟 2 (𝑟𝑚 , 𝑟𝑐 ) 𝛿 2 (𝑟𝑚 , 𝑟𝑐 )
+
2
2
𝛥𝑑𝑚
𝛥𝐷𝑀

(2.9)

where 𝛿(𝑟𝑚 , 𝑟𝑐 ) is the dose difference between the measured dose at 𝑟𝑚 and the calculated dose at
𝑟𝑐 , 𝑟(𝑟𝑚 , 𝑟𝑐 ) is the Euclidean distance between 𝑟𝑚 and 𝑟𝑐 , ∆𝑑𝑚 is the distance-to-agreement
criterion, and ∆𝐷𝑀 is the dose agreement criterion. Given a point 𝑖, 𝑗 in the reference dose, the
gamma index is defined by Low et al., as
𝛾(𝑟𝑚 ) = min{𝛤(𝑟𝑚 , 𝑟𝑐 )}∀{𝑟𝑐 }

(2.10)

Gamma analysis is used clinically as a metric by which to assess the deliverability of IMRT
and VMAT plans. The Report of the American Association of Physicists in Medicine (AAPM)
Task Group (TG) 218 recommends a distance-to-agreement of 2mm and a dose agreement value
of 3% of maximum dose with a lower threshold of 10% of maximum dose (Miften, et al. 2018).
Only reference dose points with dose values above the threshold are considered in the gamma
analysis. According to the AAPM TG 218 recommendations, treatment plans are considered to
pass if their gamma passing rate (GPR), or the number of gamma indices with value less than one
divided by the total number of points for which gamma was computed, is greater than 90%.
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Modulation Complexity Score
The modulation complexity score (MCS) was originally proposed by McNiven, et al. for
Step-N-Shoot IMRT plans (McNiven, et al. 2010). The MCS is defined between 0 and 1 and
approaches 0 as plan complexity increases. Plan complexity is computed using both the MLC leaf
sequence variability, which is a measure of the amount of MLC leaf motion during the plan, and
the aperture area variability, which is a measure of how much the aperture formed by the MLC
changes during the treatment. Masi, et al. modified the MCS to work with the continuous arcs of
VMAT, with the modified version called MCSv (Masi, et al. 2013).
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Chapter 3. Results
Verification of Log File Synchronization with Camera
The synchronization of timestamps from the log file and camera tracking system was verified
by tracking the gantry angle during a VMAT SBRT treatment. The tracked gantry angle is plotted
in Figure 3.1 with the log file record of the gantry angle during the treatment.

Figure 3.1. Comparison of tracked and log file record gantry angles. Measurement using camera
system under same conditions as respiratory tracking.
Visual inspection of Figure 3.1 suggests that no time shift is necessary between the two sets
of timestamps. To verify, cross correlation of the tracked and log file-recorded gantry angles
indicated that the agreement between the time series was maximized with no time shift applied.
From this result, we conclude that the absolute timestamps returned by the log file were
synchronized with the camera system used during this study, and that it is valid to overlay the log
file with the tracked respiratory data with no time delay between the two clocks.
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Verification of Deformable Dose Accumulation
The results of the verification of our deformable dose accumulation method to detect forced
dose errors due to interplay are shown in Figures 3.2 and 3.3. The dose profiles are displayed with
extent-of-motion (MIP Extent). It was found that the 4D accumulation method performed well
within the MIP extent, indicated by the agreement between the 4D reconstruction (solid line) and
film measurement (dotted line). However, outside the tumor motion extent the 4D reconstruction
breaks down. This can be seen by the divergence of the film from the 4D reconstruction in both
the 6 and 12 SPB cases of this validation work (Figure 3.2 and Figure 3.3, respectively). These
results indicate that the 4D reconstruction detects known dose errors due to interplay. For
comparison, the profiles of the treatment plan and static film measurement are also shown.

Figure 3.2. Superior-inferior dose profiles along principle axis of motion for validation case, 6
SPB.
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Figure 3.3. Superior-inferior dose profiles along principle axis of motion for validation case, 12
SPB.
Gamma Analysis of 4D Reconstructions with Treatment Plans
Gamma analysis was used to compare the 3 and 6 SPB 4D reconstructions with the
corresponding treatment plans, which were planned on the time-weighted average intensity
projection images (AIP). Table 3.1. presents the results for the gamma analysis, along with plan
metrics such as MU and MCSv for reference. In our gamma analysis, AAPM TG 218recommendations of 3% dose agreement and 2mm distance-to-agreement were implemented.
Values are presented for gamma calculations incorporating both a 10% and 50% threshold of
maximum dose. Above this threshold, gamma values were computed. The 50% threshold provides
an analysis of the agreement within the higher dose region; large differences between the 10% and
50% gamma passing rate indicate dose variance in the high dose region.
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Table 3.1. Gamma analysis of 4D dose reconstructions at 10% and 50% thresholds (T) compared
with static treatment plans for 3- and 6- SPB, with corresponding plan MU and VMAT
modulation complexity score (MCSv). * indicates selection for further analysis in next section.
GPR 4D vs. Plan (global 3%, 2mm)
Patient Motion
3 SPB 6 SPB 3 SPB 6 SPB
MU MCSv
Number (mm)
T=10% T=10% T=50% T=50%
1*

5

100

99.9

100

99.5

1808

0.363

2

6

100

100

100

100

2648

0.358

3

12

99.6

100

98.6

100

3033

0.482

4*

15

98.2

98.5

93.8

94.8

1425

0.471

5*

15

96.8

97.1

91

91.9

2319

0.326

6*

9

98.6

97.9

94.5

92.1

2556

0.353

7

8

100

100

100

100

2209

0.485

8

9

99.4

99.7

97.8

98.8

2243

0.389

9

6

100

100

100

100

2903

0.234

10*

5

94.1

94.7

80.8

82.7

3883

0.250

11

9

100

100

100

100

2581

0.428

12

8

100

100

100

100

2171

0.476

Mean

8.9

98.9

99

96.4

96.7

2481.6

0.385

St. Dev.

3.5

1.8

1.7

5.8

5.4

626.2

0.087

No statistically significant difference was found between the 3 and 6 SPB gamma passing
rates, using criteria 3%, 2mm was found at either dose threshold.
Comparison of Selected Patients with Film Measurement
Based on the gamma analysis results of the 4D reconstructions with the treatment plans,
we found that plans for Patients 4, 5, 6, and 10 were associated the largest dose differences within
the high dose region. In this section, we compare the selected patients’ 4D reconstructions and
treatment plans with film measurement to determine if the 4D reconstructions are in closer
agreement (higher GPR) than the treatment plans. For contrast, Patient 1 is also shown as an
example case in which the 4D reconstruction closely matches the treatment plan.
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Patient 1
We found good agreement between the 4D log file-based dose reconstruction and the
planned dose distribution for Patient 1, which are presented in Figure 3.4 and Figure 3.5 for the 3
and 6 SPB cases, respectively.

Figure 3.4. Superior-inferior dose profile for Patient 1 with breathing rate of 3 SPB.

Figure 3.5. Superior-inferior dose profile for Patient 1 with breathing rate of 6 SPB.
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These profiles correspond to gamma passing rates of 99%-100% between the 4Dreconstruction (green solid profile) and treatment plan (red dashed profile) using gamma criteria
3% and 2mm. The measured dose profile (film) is plotted for comparison, and we found little
visible difference between the measured distribution with film and either of the calculated
distributions. This corresponds to a MCSv of 0.363 and low motion amplitude of 5mm.
Gamma maps are presented in Figure 3.6 and Figure 3.7 for the 3 and 6 SPB cases,
respectively, for Patient 1. To aid in interpretation of the gamma passing and failing points, isodose
lines for 70% and 85% of max film measured dose are plotted with the gamma maps. Only values
within the MIP extent are included in the gamma calculation because of our finding that the 4D
reconstruction breaks down outside of the MIP extent.

Figure 3.6. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 1 with breathing rate 3 SPB. Color legend: (Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour and dashed and solid lines indicate film and
calculated dose, respectively.
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Figure 3.7. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 1 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
Patient 4
The measured (film), 4D reconstruction, and planned dose distributions are plotted for
Patient 4 in Figures 3.8 and 3.9. Patient 4 was associated with gamma passing rates of 93.8% (3
SPB) and 94.8% (6 SPB) between the 4D reconstruction and treatment plan as shown in Table 3.1.
The amplitude of motion for Patient 4 was 15 mm (the highest we studied), and the complexity
score was 0.471, indicating low plan complexity. Within the MIP extent (ITV contour), the 4D
dose reconstruction was found to be in better agreement with film measurement than the treatment
plan. This is within the MIP extent where the 4D reconstruction method was verified. The
deviation between 2 and 4 cm may be due to the gradient effect (‘smearing’) on the measured dose
distribution from the large motion amplitude.
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Figure 3.8. Superior-inferior profile for Patient 4 with breathing rate of 3 SPB.

Figure 3.9. Superior-inferior profile for Patient 4 with breathing rate of 6 SPB.
A possible reason that the 4D log file-based dose calculation did not reflect this is the
breakdown of the 4D deformable registration method outside of the MIP extent, beyond which the
deformable image registration algorithm lacks sufficient information to accurately map voxels.
Gamma maps for the 3 and 6 SPB measurements for Patient 4 are presented in Figures 3.10 and
3.11, respectively.
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Figure 3.10. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 4 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure 3.11. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 4 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Patient 5
Profiles for the 3 and 6 SPB measurements for Patient 5 are presented in Figure 3.12 and
Figure 3.13, respectively. Profile assessment of Patient 5 along the principle axis of motion
resulted in similar regions of agreement and of failure of the 4D reconstruction to Patient 4.

Figure 3.12. Superior-inferior dose profile for Patient 5 with breathing rate of 3 SPB.

Figure 3.13. Superior-inferior dose profile for Patient 5 with breathing rate of 6 SPB.
Gamma maps comparing the 4D reconstructions and treatment plan for Patient 5 to the 3
and 6 SPB film measurements are presented in Figure 3.14 and Figure 3.15.
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Figure 3.14. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 5 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure 3.15. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 5 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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The complexity score of this plan was lower (0.326, more complex) compared with the
plan for Patient 4 (0.471, less complex), while having the same motion amplitude (15 mm). Due
to the shape of the sine-6 wave, the sine-6 breathing pattern will result in more time spent superior
to the home position (0 cm Sup-Inf) than inferior to the home position, possibly resulting in the
delivered dose being lower than the planned dose at -1 cm. This would be attributed to the gradient
effect, not the interplay effect. Again, the 4D calculation does not accurately reflect the high dose
at the periphery, beyond the MIP extent. The gamma passing rate with film measurement for the
Patient 5 dose reconstructions in both the 3 and 6-SPB cases was much higher (3 SPB: 94.1%, 6
SPB: 98.9%) than the treatment plan (3 SPB: 77.0%, 6 SPB: 70.8%) at 3%, 2mm gamma criteria
within the MIP extent.
Patient 6
Profiles for Patient 6 at breathing rates of 3 and 6 SPB are shown in Figures 3.16 and 3.17,
respectively. Gamma maps for Patient 6 are presented in Figures 3.18 and 3.19.

Figure 3.16. Superior-inferior dose profile for Patient 6 with breathing rate of 3 SPB.
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Figure 3.17. Superior-inferior dose profile for Patient 6 with breathing rate of 6 SPB.
4D reconstruction resulted in a higher dose at the center of motion than both the static
planned distribution and film measurement.

Figure 3.18. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 6 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
40

Figure 3.19. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 6 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
The 4D reconstruction slightly underperformed when compared with film measurement
than the treatment plan to the AIP image. This is quantified by a lower gamma passing rate of the
4D reconstruction with film (3 SPB: 95.9%, 6 SPB: 95.3%) within the MIP extent than the
treatment plan with film (3 SPB: 98.9%, 6 SPB: 98.3%). Patient 6 was associated with 9 mm of
tumor motion and a complexity score of 0.353.
Patient 10
Dose profiles for Patient 10 are presented in Figure 3.20 and Figure 3.21. The 4D
reconstruction for Patient 10 exhibited better agreement with film measurement than the treatment
plan. This plan had an MCSv of 0.250, with low tumor motion (5 mm amplitude). The 4D
reconstruction of the moving target dose had a higher gamma passing rate when compared with
the film measurement for both breathing rates (3 SPB: 82.0%, 6 SPB: 93.4%) than the treatment
plan compared with the film measurement (3 SPB: 67.2%, 6 SPB: 67.1%).
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Figure 3.20. Superior-inferior dose profile for Patient 10 with breathing rate of 3 SPB.

Figure 3.21. Superior-inferior dose profile for Patient 10 with breathing rate of 6 SPB.
Gamma maps for Patient 10 are presented in Figure 3.22 and Figure 3.23. Due to the low
amplitude, it is unlikely that motion effects resulted in the dose deviation within the high dose
region. Instead, due to the high complexity this dose error may be due to plan deliverability by the
linear accelerator.

42

Figure 3.22. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 10 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure 3.23. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 10 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Statistical Analysis of Gamma Passing Rates with Film
Gamma passing rates (GPR) were computed within the MIP extent (ITV contour) for the 4D
reconstructions and treatment plans with film measurement to determine the level of agreement
between each of the computed doses and the measured dose. These computations were performed
for each patient at both breathing rate of 3 and 6 SPB, and with gamma criteria 3% global dose
agreement and 2mm distance to agreement. Table 3.2 presents the gamma analysis results for all
patients in our cohort. GPR difference was defined as the difference between the GPR of the 4D
reconstruction vs. film, minus the GPR of the treatment plan vs. film in each case.
Table 3.2. Gamma passing rates (calculated vs. measured) within the MIP extent for all patient
plans delivered to phantom. Bold indicates statistical significance (p < 0.05). GPR Difference
computed as GPR(4D, Film) – GPR(Plan, Film).
Gamma Passing Rate within MIP
Gamma Passing Rate within MIP
3 SPB (3%, 2mm)
6 SPB (3%, 2mm)
Patient
Number
Plan vs
GPR
GPR 4D
GPR Plan
GPR
4D vs Film
Film
Difference
vs. Film
vs. Film
Difference
1

99.3

99.53

-0.23

98.36

97.42

0.94

2

97.88

98.21

-0.33

98.99

98.88

0.11

3

87.56

87.1

0.46

85.44

82.03

3.41

4

89.42

77.73

11.69

91.14

83.58

7.56

5

94.07

77.04

17.03

98.88

70.85

28.03

6

95.91

98.87

-2.96

95.7

98.26

-2.56

7

97.7

90.49

7.21

94.36

94.46

-0.1

8

97.44

90.79

6.65

99.8

96.11

3.69

9

97.88

97.88

0

99.66

98.21

1.45

10

81.95

62.72

19.23

93.43

67.06

26.37

11

98.26

90.58

7.68

99.28

100

-0.72

12

100

97.49

2.51

100

99.58

0.42

Mean

94.78

89.04

5.75

96.25

90.54

5.72

Median

97.57

90.69

4.58

98.62

96.77

1.2

St. Dev.

5.57

11.35

7.21

4.48

11.73

10.36
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Figures 3.24 and 3.25 present plots of gamma passing rates for the 4D reconstructions and
treatment plans vs. film measurement within the MIP extent for the 3 and 6 SPB breathing rates,
respectively.

Gamma Passing Rate within MIP (%)
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and 4D Reconstruction vs. Film, 3 SPB
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Figure 3.24. Gamma passing rates (4D reconstruction vs. film, treatment plan vs. film) within
MIP extent with criteria global 3%, 2mm for all 12 patients at breathing rate of 3 SPB. Lines
drawn as a visual aid.
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Figure 3.25. Gamma passing rates (4D reconstruction vs. film, treatment plan vs. film) within
MIP extent with criteria global 3%, 2mm for all 12 patients at breathing rate of 3 SPB. Lines
drawn as a visual aid.
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A positive GPR difference value indicates that the 4D reconstruction outperformed the
treatment plan in comparison with the film measurement. The mean gamma passing rates within
the MIP for the 3 SPB breathing rate were found to be 94.8% ± 5.5% for the 4D accumulation vs.
film and 89.0% ± 7.2% for the treatment plans vs. film. Median GPR values for the 3 SPB
breathing rate were respectively 97.6% and 90.7%. The median GPR differences across all patients
were +4.58% for the 3 SPB measurements and +1.2% for the 6 SPB measurements. Both median
GPR differences were found to be statistically significant (p = 0.013 and p=0.017, respectively),
according to a Wilcoxon signed-rank test of the data. A box plot presenting the aggregate GPR
differences for both breathing rates across all patients is shown in Figure 3.26.

Figure 3.26. Gamma passing rate difference for breathing rates of 3 and 6 SPB for all patient
plans delivered to phantom. Positive difference value indicates 4D dose reconstruction resulted
in a higher GPR with film measurement than the treatment plan copied to the phantom. Values of
statistical significance displayed as p-values for the median. P-values computed using Wilcoxon
signed-rank test. Mean GPR difference displayed as filled circles.
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Chapter 4. Discussion and Conclusions
Summary of Findings
In this work, we developed and tested a procedure for utilizing Elekta machine log files to
retrospectively calculate the dose to the moving target during lung SBRT. To accomplish this, we
used a programmable respiratory phantom as a surrogate for a lung cancer patient undergoing lung
SBRT. The programmable respiratory phantom allowed us to place radiochromic film at the
treatment isocenter and measure dose to a target moving in the superior-inferior direction. We
reconstructed moving target dose for 12 clinical SBRT plans at 2 breathing rates (a clinically
realistic 3 SPB and longer 6 SPB) and compared our reconstructed doses to the measured film
doses. In addition, we compared the reconstructed doses to their corresponding static plans using
gamma analysis. All reconstructed (4D) planar dose distributions had a gamma passing rate above
94% when compared with the corresponding static plans, using the AAPM TG 218 recommended
criteria for IMRT patient-specific quality assurance (3%, 2mm, and 10% threshold) (Miften, et al.
2018).
Further gamma analysis using a more restrictive threshold (50%) allowed us to pinpoint
cases in which motion resulted in dose deviations from the static plan within the high dose region.
These cases were further considered by comparison with film. Profile comparison and gamma
analysis of the treatment plans and 4D reconstructed doses with film measurement indicated that
for 3 of the 4 studied cases with notable discrepancy, the film measurement more closely agreed
with the 4D reconstruction than the static plan (Patients 4, 5, and 10).
We found that when considering the 4D dose reconstructions for all of the patients, the
gamma passing between the 4D dose reconstruction and the film measurement was significantly
higher according to the Wilcoxon signed-rank test (3 SPB, p=0.013; 6 SPB, p=0.017) for both
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breathing rates within the tumor motion extent (within the MIP ITV contour) than the gamma
passing rate between the treatment plan to static geometry and the film. This holds true to our
expectations, and further verifies the 4D dose reconstruction method utilizing 4D-CT imaging.
To our knowledge, this is the first film-based end-to-end verification of log file-based dose
reconstruction to moving targets during lung SBRT using 4D-CT imaging. Previously, Zou et al.
simulated motion effects on dose using a similar 4D-CT based methodology (Zou, et al. 2014).
However, in their study, motion was simulated in the treatment planning system and was not
delivered to phantom or measured using film. In a study similar to this study, Poulsen, et al.
performed an end-to-end verification of their isocenter shift method in which intrafraction
respiratory motion was combined with the machine log data and log file control points were
assigned an isocenter position based on the respiratory trace position at corresponding time points
(Poulsen, et al. 2012). The incorporation of 4D-CT imaging into the determination of movingtarget dose provides a first-order approximation of the deformation of the anatomy of the patient
at each breathing phase during treatment. Hence, the dose to moving normal tissues may also be
accounted for, as well as the effect of tumor deformation during respiration. Both of these benefits
assume that the time-dependent patient internal anatomy during 4D-CT remains consistent during
their course of treatment.
Limitations of this Work
In our study, lung SBRT plans were delivered to a programmable respiratory phantom,
which allowed us to test our dose reconstruction under controlled respiratory motion which was
identical during 4D-CT imaging and beam delivery. Exact reproducibility of the breathing pattern
from 4D-CT to treatment is unrealistic to a clinical scenario with a real patient given the variability
in patient breathing cycles over time (Mageras, et al. 2004) (Keall, et al. 2006) (Sonke, et al. 2008).
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In addition, the phantom remained static on the treatment couch during beam delivery, which is
again unrealistic to actual patient treatment conditions (i.e, small movements of the patient during
treatment) and represents an ideal situation. Both of these inconsistencies between delivering
beams to a phantom and to a real patient will cause deviation of the 4D reconstruction from the
actual delivered dose.
In lieu of generating plans made specifically for the phantom geometry, real patient plans
were copied onto the phantom. Due to the geometrical differences between the real patients and
the phantom, the computed dose to the phantom may have contained dose heterogeneities and
falloff within the region of tumor motion not found within the real patient plans. Thus, plans copied
to the phantom may have been more susceptible to tumor motion than the original plans to the
patients. However, the treatment plans copied to the phantom still provided a valid baseline upon
which to compare the 4D dose reconstructions because the geometrical setup of both dose
computations (planned and reconstructed) remained consistent.
Next, we saw a breakdown of the 4D dose reconstruction outside of the MIP extent; the
region outside of the MIP extent is still within the PTV due to the setup margin, and these results
suggest that 4D dose reconstruction may yield incorrect dose to the peripheral portion of the PTV.
However, intensity-based DIR has been previously shown to have decreased performance in lowcontrast regions (Zhong, et al. 2012). Thus, the breakdown of the 4D dose reconstruction outside
of the MIP extent may have been associated with the homogeneity of the phantom and lack of
spatial information surrounding the tumor. It has been shown that, for similar DIR performance in
phantom images to a real patient images, the phantom should have similar density heterogeneity
to the patient (Kirby, et al. 2013). This suggests that the 4D reconstruction will perform better
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outside the MIP extent in real patient cases than it does in the case of the Quasar phantom, since
patient images provide increased tissue heterogeneity in the region surrounding the tumor.
Future Work
The Quasar phantom has several cylindrical insert types, including an insert that has been
drilled for an ion chamber. Therefore, ion chamber measurements may be used to further validate
the 4D dose reconstruction method and provide normalization for subsequent film measurements
(i.e., correct for daily machine output variance, which was not accounted for in this study). The
4D dose reconstruction procedure is time and labor intensive (approximately 2 hours per
reconstruction) and the isocenter shift method is much faster (during the isocenter shift method,
beams are only computed on one image (Poulsen, et al. 2012); in a 4D dose reconstruction, beams
are computed on all 4D-CT images). Thus, the clinical utility of performing a full 4D dose
reconstruction using 4D-CT should be understood. The dose reconstruction quality difference
between the two methods could be assessed using a deformable respiratory phantom, as this would
better represent the internal deformation of patient anatomy.
Later work should consider the variability of internal patient anatomy caused by respiration
during treatment delivery and incorporate this information into the 4D dose reconstruction. To
accommodate this, on-board imaging with cone-beam CT (CBCT) during beam delivery may
allow mapping between the patient anatomy during the treatment and during the 4D-CT images
taken at the start of their treatment cycle. On-board imaging during beam delivery has been studied
for the purpose of determining intra-fraction tumor motion; these methods include both partial-arc
CBCT reconstruction and fluoroscopy using the on-board CBCT imager (Haytmyradov, et al.
2019,Shieh, et al. 2015). By finding the deformation mapping between the intra-fraction on-board
imaging and the corresponding 4D-CT images taken during the planning phase, intra-fraction
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anatomical variation could be incorporated into the 4D-CT based dose reconstruction presented in
this work. However, the addition of on-board imaging during treatment would increase the
radiation dose to the patient, and the trade-off between increased dose reconstruction accuracy and
increased patient dose must be considered.
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Appendix A. Superior-Inferior Dose Profiles

Figure A.1. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 1 at a breathing rate of 3 SPB.

Figure A.2. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 1 at a breathing rate of 6 SPB.
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Figure A.3. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 2 at a breathing rate of 3 SPB.

Figure A.4. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 2 at a breathing rate of 6 SPB.
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Figure A.5. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 3 at a breathing rate of 3 SPB.

Figure A.6. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 3 at a breathing rate of 6 SPB.
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Figure A.7. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 4 at a breathing rate of 3 SPB.

Figure A.8. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 4 at a breathing rate of 6 SPB.
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Figure A.9. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 5 at a breathing rate of 3 SPB.

Figure A.10. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 5 at a breathing rate of 6 SPB.
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Figure A.11. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 6 at a breathing rate of 3 SPB.

Figure A.12. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 6 at a breathing rate of 6 SPB.
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Figure A.13. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 7 at a breathing rate of 3 SPB.

Figure A.14. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 7 at a breathing rate of 6 SPB.
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Figure A.15. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 8 at a breathing rate of 3 SPB.

Figure A.16. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 8 at a breathing rate of 6 SPB.
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Figure A.17. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 9 at a breathing rate of 3 SPB.

Figure A.18. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 9 at a breathing rate of 6 SPB.
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Figure A.19. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 10 at a breathing rate of 3 SPB.

Figure A.20. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 10 at a breathing rate of 6 SPB.
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Figure A.21. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 11 at a breathing rate of 3 SPB.

Figure A.22. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 11 at a breathing rate of 6 SPB.
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Figure A.23. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 12 at a breathing rate of 3 SPB.

Figure A.24. Superior-inferior dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 12 at a breathing rate of 6 SPB.
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Appendix B. Lateral Dose Profiles

Figure B.1. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 1 at a breathing rate of 3 SPB.

Figure B.2. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 1 at a breathing rate of 6 SPB.
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Figure B.3. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 2 at a breathing rate of 3 SPB.

Figure B.4. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 2 at a breathing rate of 6 SPB.
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Figure B.5. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 3 at a breathing rate of 3 SPB.

Figure B.6. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 3 at a breathing rate of 6 SPB.
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Figure B.7. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 4 at a breathing rate of 3 SPB.

Figure B.8. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 4 at a breathing rate of 6 SPB.
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Figure B.9. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 5 at a breathing rate of 3 SPB.

Figure B.10. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 5 at a breathing rate of 6 SPB.
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Figure B.11. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 6 at a breathing rate of 3 SPB.

Figure B.12. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 6 at a breathing rate of 6 SPB.
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Figure B.13. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 7 at a breathing rate of 3 SPB.

Figure B.14. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 7 at a breathing rate of 6 SPB.
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Figure B.15. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 8 at a breathing rate of 3 SPB.

Figure B.16. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 8 at a breathing rate of 6 SPB.
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Figure B.17. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 9 at a breathing rate of 3 SPB.

Figure B.18. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 9 at a breathing rate of 6 SPB.
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Figure B.19. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 10 at a breathing rate of 3 SPB.

Figure B.20. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 10 at a breathing rate of 6 SPB.
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Figure B.21. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 11 at a breathing rate of 3 SPB.

Figure B.22. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 11 at a breathing rate of 6 SPB.
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Figure B.23. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 12 at a breathing rate of 3 SPB.

Figure B.24. Lateral dose profiles showing film measurement, treatment plan, and 4D
reconstructed dose, for Patient 12 at a breathing rate of 6 SPB.
75

Appendix C. Gamma Analysis

Figure C.1. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 1 with breathing rate 3 SPB. Color legend: (Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour and dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.2. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 1 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point.
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Figure C.3. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 2 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.4. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 2 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.5. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 3 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.6. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 3 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.7. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 4 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.8. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 4 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.9. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 5 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.10. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 5 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.11. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 6 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.12. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 6 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.13. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 7 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.14. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 7 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.15. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 8 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.16. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 8 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.17. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 9 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.18. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 9 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.19. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 10 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.20. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 10 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.21. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 11 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.22. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 11 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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Figure C.23. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 12 with breathing rate 3 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.

Figure C.24. Gamma map (global 3%, 2mm) for 4D reconstruction and treatment plan vs. film
measurement, within MIP extent, for Patient 12 with breathing rate 6 SPB. Color legend: Gray:
Point not included in calculation; White: Passing point; Red: Failing point. Circle and square
markers indicate 70% and 85% isodose contour. Dashed and solid lines indicate film and
calculated dose, respectively.
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